JP2005523891A - ペプチド構築物を用いる疾患もしくは状態の治療方法 - Google Patents

ペプチド構築物を用いる疾患もしくは状態の治療方法 Download PDF

Info

Publication number
JP2005523891A
JP2005523891A JP2003561535A JP2003561535A JP2005523891A JP 2005523891 A JP2005523891 A JP 2005523891A JP 2003561535 A JP2003561535 A JP 2003561535A JP 2003561535 A JP2003561535 A JP 2003561535A JP 2005523891 A JP2005523891 A JP 2005523891A
Authority
JP
Japan
Prior art keywords
peptide
polypeptide
antigen
derg
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003561535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523891A5 (https=
Inventor
ジマーマン，ダニエル・エイチ
シヤローンビト，ユピン
ローゼンタール，ケネス・エス
エラン，マイク
Original Assignee
セル−サイ・コーポレーシヨン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル−サイ・コーポレーシヨン filed Critical セル−サイ・コーポレーシヨン
Publication of JP2005523891A publication Critical patent/JP2005523891A/ja
Publication of JP2005523891A5 publication Critical patent/JP2005523891A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003561535A 2002-01-23 2003-01-23 ペプチド構築物を用いる疾患もしくは状態の治療方法 Withdrawn JP2005523891A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34998202P 2002-01-23 2002-01-23
US34998302P 2002-01-23 2002-01-23
US35003202P 2002-01-23 2002-01-23
PCT/US2003/001816 WO2003061589A2 (en) 2002-01-23 2003-01-23 Methods for treating diseases or conditions with peptide constructs

Publications (2)

Publication Number Publication Date
JP2005523891A true JP2005523891A (ja) 2005-08-11
JP2005523891A5 JP2005523891A5 (https=) 2006-03-09

Family

ID=27617581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561535A Withdrawn JP2005523891A (ja) 2002-01-23 2003-01-23 ペプチド構築物を用いる疾患もしくは状態の治療方法

Country Status (5)

Country Link
US (1) US20070003542A1 (https=)
EP (1) EP1485466A4 (https=)
JP (1) JP2005523891A (https=)
AU (1) AU2003237493A1 (https=)
WO (1) WO2003061589A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529065A (ja) * 2002-01-23 2005-09-29 セル−サイ・コーポレーシヨン 疾患を治療するためのペプチド構築物
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US8178649B2 (en) * 2004-12-07 2012-05-15 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US7811995B2 (en) * 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US8496942B2 (en) * 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
WO2010085661A1 (en) * 2009-01-23 2010-07-29 Musc Foundation For Reasearch Development Modified peptides and their use
WO2014165164A2 (en) * 2013-03-12 2014-10-09 Albany Medical College Compositions and methods for treating autoimmune diseases
JP6740250B2 (ja) 2015-04-27 2020-08-12 スサヴィオン バイオサイエンシーズ インコーポレイテッド がんおよび持続性ウイルス感染を処置するための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
EP1030819A4 (en) * 1997-09-30 2001-11-21 Cel Sci Corp CONJUGATED IMMUNOGENIC POLYPEPTIDE FOR THE TREATMENT OF HERPES SIMPLEX VIRUS
WO2001036448A2 (en) * 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
AU4705201A (en) * 1999-10-27 2001-06-25 Cel-Sci Corporation Peptide constructs for treating autoimmune and related diseases
US6951647B2 (en) * 2001-05-24 2005-10-04 Cel-Sci Corporation T cell binding ligand peptides and method of inducing a cellular immune response
JP2005529065A (ja) * 2002-01-23 2005-09-29 セル−サイ・コーポレーシヨン 疾患を治療するためのペプチド構築物

Also Published As

Publication number Publication date
US20070003542A1 (en) 2007-01-04
AU2003237493A1 (en) 2003-09-02
EP1485466A4 (en) 2005-09-14
WO2003061589A3 (en) 2004-05-27
WO2003061589A2 (en) 2003-07-31
EP1485466A2 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
EP1379552B2 (en) Toll-like receptor 5 ligands and methods of use
US8741576B2 (en) Heteroclitic analogs and related methods
US20200157146A1 (en) Controlled modulation of amino acid side chain length of peptide antigens
US6602510B1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20080279924A1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
TW200307557A (en) Stabilized synthetic immunogen delivery systems
JP2001521386A (ja) 被修飾ＴＮＦα分子、このような被修飾ＴＮＦα分子をコードするＤＮＡ、並びにこのような被修飾ＴＮＦα分子及びＤＮＡを具備するワクチン
JPH03173830A (ja) ワクチン組成物
SA519410007B1 (ar) مركبات ببتيد وطرق لمعالجة السكر
US20030175285A1 (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
JP2001518455A (ja) 単純疱疹ウイルスの処置のための免疫原性の複合ポリペプチド
US6923973B1 (en) Peptide and DNA immunization against Coccidioides immitis infections
JP2005523891A (ja) ペプチド構築物を用いる疾患もしくは状態の治療方法
US7378100B2 (en) Fusion protein for inhibiting cervical cancer
JP2005528373A (ja) 免疫プロトコルにＦｌｔ３リガンドを用いる方法
JP4299777B2 (ja) 免疫応答を誘導するための方法および組成物
JP2005529065A (ja) 疾患を治療するためのペプチド構築物
Francis et al. Increasing cellular immunogenicity to peptide-based vaccine candidates using a fluorocarbon antigen delivery system
EP2987502B1 (en) Peptide adjuvants
CN103608031B (zh) 用于治疗IFNα相关病况的方法
JP2022542120A (ja) 抗原性ポリペプチドおよびその使用方法
WO2010129710A1 (en) Use of rankl to induce differentiation of microfold cells (m cells)
US20140147490A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
WO2022174151A1 (en) Prophylactic broad spectrum vaccine for sars-cov-2
US20040072340A1 (en) Use of peptide vectors to improve the immune response to antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060123

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060629